AEON Biopharma, a Phase 2 biotech developing a botulinum toxin therapy for neuro and gastroenterology indications, withdrew its plans for an initial public offering on Wednesday. It had filed to raise $75 million by offering 5 million shares at a price range of $14 to $16, but postponed ahead of pricing in October.
The Newport Beach, CA-based company was founded in 2012 and booked $1 million in revenue for the 12 months ended June 30, 2021. It had planned to list on the Nasdaq under the symbol AEON. Wells Fargo Securities, Cantor Fitzgerald, Mizuho Securities, and H.C. Wainwright were set to be the joint bookrunners on the deal.
